MARKET

GENE

GENE

Genetic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.160
-0.370
-8.17%
Pre Market: 4.100 -0.06 -1.44% 08:36 03/05 EST
OPEN
4.570
PREV CLOSE
4.530
HIGH
4.686
LOW
3.910
VOLUME
2.12K
TURNOVER
--
52 WEEK HIGH
10.30
52 WEEK LOW
1.408
MARKET CAP
62.48M
P/E (TTM)
-6.6827
1D
5D
1M
3M
1Y
5Y
SKT, BLRX, LPCN and ECOR among premarket gainers
Severn Bancorp (SVBI) +82% on merger agreement with Shore Bancshares.Tanger Factory Outlet Centers (SKT) +21%.Allied Esports Entertainment Inc. (AESE) +19%.Bellicum Pharmaceuticals (BLCM) +14%. on first reported use of CaspaCIDe® Safety Switch.Soligenix
Seekingalpha · 1d ago
Genetic Technologies inks distribution deal for COVID risk test
Genetic Technologies (GENE) has secured a co-exclusive three-year agreement with US-based Infinity BiologiX for the production, distribution and sale of its COVID-19 Serious Disease Risk Test in U.S. IBX is required
Seekingalpha · 1d ago
Genetic Technologies Signs Multi-Year US Distribution Agreement for COVID Risk Test
GlobeNewswire · 1d ago
MFGP, RIOT, MARA and TRXC among premarket gainers
Ovid Therapeutics (OVID) +73% after soticlestat deal with Takeda.KemPharm (KMPH) +69% on FDA approval of ADHD drug.Ocugen, Inc. (OCGN) +39% on Indian partner’s COVID-19 vaccine efficacy data.Asensus Surgical (TRXC) +33% on FDA clearance for
Seekingalpha · 2d ago
Genetic Technologies Announced a Co-exclusive Production and Distribution Rights and License Agreement with Infinity BiologiX LLC for its COVID-19 Serious Disease Risk Test in the U.S.
Genetic Technologies Limited (NASDAQ: GENE) is pleased to announce a co-exclusive production and distribution rights and license agreement (‘Agreement') with US Based Infinity BiologiX LLC (‘IBX'), a leading central laboratory providing sample collection a...
Benzinga · 2d ago
BRIEF-Genetic Technologies Signs License Agreement With Infinity Biologix
reuters.com · 2d ago
Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report(R)
MELBOURNE, Australia, Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- MELBOURNE, Australia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:...
GlobeNewswire · 6d ago
Cannabis Stock Gainers And Losers From February 23, 2021
GAINERS: Rhinomed (OTCQB: RHNMF) shares closed up 19.94% at $0.10
Benzinga · 02/23 22:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GENE. Analyze the recent business situations of Genetic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 267.68K
% Owned: 1.78%
Shares Outstanding: 15.02M
TypeInstitutionsShares
Increased
5
47.43K
New
7
22.35K
Decreased
1
9.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
-1.99%
Healthcare Providers & Services
-0.32%
Key Executives
Chairman/Director
Peter Rubenstein
Chief Executive Officer
George Muchnicki
Chief Executive Officer
Simon Morriss
Chief Financial Officer
Phillip Hains
Corporate Executive
Mark Ostrowski
Chief Operating Officer
Stan Sack
Executive Director
Jerzy Muchnicki
Other
Richard Allman
Other
M. Luisa Ashdown
Other
Susan Gross
Other
Diana Newport
Secretary
Justyn Stedwell
Non-Executive Director
Nick Burrows
Non-Executive Independent Director
Lindsay Wakefield
No Data
About GENE
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

Webull offers kinds of Genetic Technologies Limited (ADR) stock information, including NASDAQ:GENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GENE stock methods without spending real money on the virtual paper trading platform.